AOD-9604 vs Tesamorelin

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; preclinical studies in obese mice demonstrated lipolytic effects and body weight reduction. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains a preclinical study in obese mice demonstrating effects on lipid metabolism. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and the compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before subcutaneous administration; the volume of BAC water added to the vial determines the concentration of the resulting solution, following standard peptide reconstitution methodology. Research on AOD-9604 peptide dosage was conducted in both the preclinical obese-mouse model and the Phase 2/3 human clinical program in adult obesity populations; clinical trial dosage data exists from the Metabolic Pharmaceuticals program, though primary results were not published in indexed peer-reviewed journals. Oral formulations of AOD-9604 were also evaluated in the clinical program as an alternative to subcutaneous delivery. AOD-9604 dosage context In the Metabolic Pharmaceuticals clinical program, AOD-9604 was evaluated at oral doses of 1mg and 9mg daily, and via subcutaneous injection at approximately 1mg/day in Phase 2/3 human obesity studies. In the research peptide community, subcutaneous protocols commonly reference 250–300mcg once daily, administered to the subcutaneous adipose tissue of the abdomen. These figures derive from the research context rather than an approved clinical protocol — AOD-9604 has no approved dosing for any human indication. Reconstitution follows standard peptide preparation: a 5mg vial combined with 2mL bacteriostatic water yields 2,500mcg/mL (0.1mL = 250mcg per injection). Oral formulations were evaluated in the clinical trial as a potential non-injectable route; no commercial oral AOD-9604 product exists. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.

Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.

Tesamorelin (GHRH(1-44)-trans-3-hexenoic acid; Egrifta) is a synthetic 44-amino-acid analog of endogenous growth hormone-releasing hormone conjugated with a trans-3-hexenoic acid moiety to confer resistance to DPP-IV enzymatic degradation and extend its plasma stability, developed and approved as the first GHRH analog indicated for a metabolic complication of HIV antiretroviral therapy — specifically visceral adiposity from HIV-associated lipodystrophy. Tesamorelin activates GHRH receptors on pituitary somatotrophs to stimulate pulsatile GH secretion and downstream hepatic IGF-1 production; the resulting normalization of GH pulse amplitude in treated patients reduces visceral adipose tissue through lipolytic signaling in visceral fat depots, without the risk of direct supraphysiological GH administration. A pivotal Phase 3 randomized placebo-controlled trial in HIV-infected adults on antiretroviral therapy demonstrated significant and sustained reductions in visceral adipose tissue area by MRI imaging versus placebo, with a favorable safety profile in this immunocompromised population, providing the pivotal evidence for FDA approval in 2010. Tesamorelin (Egrifta, Theratechnologies) is FDA-approved and requires a prescription; it is indicated specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy and is not approved for general fat loss, body composition improvement, anti-aging, or GH deficiency applications outside the HIV-lipodystrophy indication. Tesamorelin dosage and where to get it: Tesamorelin (Egrifta) is administered as a once-daily subcutaneous injection of 2mg in its FDA-approved indication for HIV-associated lipodystrophy; this is the only dose and indication with established clinical evidence. In off-label research contexts examining body composition and GH axis support in non-HIV populations, tesamorelin has been studied at similar dose ranges, though no approved protocol exists for these applications. Where to find tesamorelin: as an FDA-approved prescription medication, tesamorelin is available through licensed pharmacies in the United States with a valid prescription. Compounding pharmacies may also prepare tesamorelin for off-label clinical use under physician supervision. Telehealth providers specializing in peptide therapy and hormone health sometimes offer tesamorelin consultations for eligible patients. PeptideBase maintains a directory of verified providers — including telehealth platforms — for those researching access to tesamorelin through supervised clinical channels.